These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29067902)

  • 21. Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price.
    Amick AK; Eskibozkurt GE; Hosek SG; Flanagan CF; Landovitz RJ; Jin EY; Wilson CM; Freedberg KA; Weinstein MC; Kazemian P; Paltiel AD; Ciaranello AL; Neilan AM
    Clin Infect Dis; 2024 Feb; 78(2):402-410. PubMed ID: 37823865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating the impact of prioritization of antiretroviral pre-exposure prophylaxis in New York.
    Kessler J; Myers JE; Nucifora KA; Mensah N; Toohey C; Khademi A; Cutler B; Braithwaite S
    AIDS; 2014 Nov; 28(18):2683-91. PubMed ID: 25493594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preparing for PrEP: estimating the size of the population eligible for HIV pre-exposure prophylaxis among men who have sex with men in England.
    Mitchell HD; Desai S; Mohammed H; Ong KJ; Furegato M; Hall V; Desai M; Saunders JM; Hughes G; Field N; Gill ON
    Sex Transm Infect; 2019 Nov; 95(7):484-487. PubMed ID: 31010953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can we afford to offer pre-exposure prophylaxis to MSM in Catalonia? Cost-effectiveness analysis and budget impact assessment.
    Reyes-Urueña J; Campbell C; Diez E; Ortún V; Casabona J
    AIDS Care; 2018 Jun; 30(6):784-792. PubMed ID: 29262694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of HIV pre-exposure prophylaxis in Japan.
    Mizushima D; Nagai Y; Mezzio D; Harada K; Piao Y; Barnieh L; El Moustaid F; Cawson M; Taniguchi T
    J Med Econ; 2023; 26(1):886-893. PubMed ID: 37421417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness and impact of pre-exposure prophylaxis to prevent HIV among men who have sex with men in Asia: A modelling study.
    Ten Brink DC; Martin-Hughes R; Minnery ME; Osborne AJ; Schmidt HA; Dalal S; Green KE; Ramaurtarsing R; Wilson DP; Kelly SL
    PLoS One; 2022; 17(5):e0268240. PubMed ID: 35617169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of combination prevention strategies on HIV incidence among gay and bisexual men who have sex with men in the UK: a model-based analysis.
    Cambiano V; Miners A; Lampe FC; McCormack S; Gill ON; Hart G; Fenton KA; Cairns G; Thompson M; Delpech V; Rodger AJ; Phillips AN
    Lancet HIV; 2023 Nov; 10(11):e713-e722. PubMed ID: 37923485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India.
    Kazemian P; Costantini S; Kumarasamy N; Paltiel AD; Mayer KH; Chandhiok N; Walensky RP; Freedberg KA
    Clin Infect Dis; 2020 Feb; 70(4):633-642. PubMed ID: 30921454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gonorrhoea and chlamydia diagnosis as an entry point for HIV pre-exposure prophylaxis: a modelling study.
    Kasaie P; Schumacher CM; Jennings JM; Berry SA; Tuddenham SA; Shah MS; Rosenberg ES; Hoover KW; Gift TL; Chesson H; German D; Dowdy DW
    BMJ Open; 2019 Mar; 9(3):e023453. PubMed ID: 30837248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda.
    Ying R; Sharma M; Heffron R; Celum CL; Baeten JM; Katabira E; Bulya N; Barnabas RV
    J Int AIDS Soc; 2015; 18(4 Suppl 3):20013. PubMed ID: 26198348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries.
    Pretorius C; Schnure M; Dent J; Glaubius R; Mahiane G; Hamilton M; Reidy M; Matse S; Njeuhmeli E; Castor D; Kripke K
    J Int AIDS Soc; 2020 Feb; 23(2):e25451. PubMed ID: 32112512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.
    Long EF; Stavert RR
    J Gen Intern Med; 2013 Oct; 28(10):1294-301. PubMed ID: 23588668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.
    Glaubius RL; Hood G; Penrose KJ; Parikh UM; Mellors JW; Bendavid E; Abbas UL
    Clin Infect Dis; 2016 Aug; 63(4):539-47. PubMed ID: 27193745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study.
    Phillips AN; Bershteyn A; Revill P; Bansi-Matharu L; Kripke K; Boily MC; Martin-Hughes R; Johnson LF; Mukandavire Z; Jamieson L; Meyer-Rath G; Hallett TB; Ten Brink D; Kelly SL; Nichols BE; Bendavid E; Mudimu E; Taramusi I; Smith J; Dalal S; Baggaley R; Crowley S; Terris-Prestholt F; Godfrey-Faussett P; Mukui I; Jahn A; Case KK; Havlir D; Petersen M; Kamya M; Koss CA; Balzer LB; Apollo T; Chidarikire T; Mellors JW; Parikh UM; Godfrey C; Cambiano V;
    Lancet HIV; 2022 May; 9(5):e353-e362. PubMed ID: 35489378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.
    Smith J; Bansi-Matharu L; Cambiano V; Dimitrov D; Bershteyn A; van de Vijver D; Kripke K; Revill P; Boily MC; Meyer-Rath G; Taramusi I; Lundgren JD; van Oosterhout JJ; Kuritzkes D; Schaefer R; Siedner MJ; Schapiro J; Delany-Moretlwe S; Landovitz RJ; Flexner C; Jordan M; Venter F; Radebe M; Ripin D; Jenkins S; Resar D; Amole C; Shahmanesh M; Gupta RK; Raizes E; Johnson C; Inzaule S; Shafer R; Warren M; Stansfield S; Paredes R; Phillips AN;
    Lancet HIV; 2023 Apr; 10(4):e254-e265. PubMed ID: 36642087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness Analysis of a National Pre-Exposure Prophylaxis (PrEP) Program in Ireland.
    O Murchu E; Teljeur C; Hayes C; Harrington P; Moran P; Ryan M
    Value Health; 2021 Jul; 24(7):948-956. PubMed ID: 34243838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study.
    Gomez GB; Borquez A; Caceres CF; Segura ER; Grant RM; Garnett GP; Hallett TB
    PLoS Med; 2012; 9(10):e1001323. PubMed ID: 23055836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of HIV pre-exposure prophylaxis among men who have sex with men in England: data from the AURAH2 prospective study.
    Hanum N; Cambiano V; Sewell J; Phillips AN; Rodger AJ; Speakman A; Nwokolo N; Asboe D; Gilson R; Clarke A; Miltz AR; Collins S; Lampe FC;
    Lancet Public Health; 2020 Sep; 5(9):e501-e511. PubMed ID: 32888443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Piloting a partially self-financed mode of human immunodeficiency virus pre-exposure prophylaxis delivery for men who have sex with men in Hong Kong.
    Lee SS; Kwan TH; Wong NS; Lee KCK; Chan DPC; Lam TTN; Lui GCY
    Hong Kong Med J; 2019 Oct; 25(5):382-391. PubMed ID: 31619578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-exposure prophylaxis (PrEP) for MSM in low HIV incidence places: should high risk individuals be targeted?
    Wong NS; Kwan TH; Tsang OTY; Lee MP; Yam WC; Lam W; Leung WS; Chan JMC; Ho KM; Lee SS
    Sci Rep; 2018 Aug; 8(1):11641. PubMed ID: 30076362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.